ARDX - Ardelyx Inc Stock Price, Fair Value and News

6.45USD-0.10 (-1.53%)Market Closed

Market Summary

USD6.45-0.10

Market Closed

-1.53%

ARDX Alerts

1 major insider sales recently.

ARDX Stock Price

View Fullscreen

ARDX RSI Chart

ARDX Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-23.07

Price/Sales (Trailing)

12.25

EV/EBITDA

-25.35

Price/Free Cashflow

-16.92

ARDX Price/Sales (Trailing)

ARDX Profitability

Operating Margin

95.53%

EBT Margin

-52.65%

Return on Equity

-39.6%

Return on Assets

-22.2%

Free Cashflow Yield

-5.91%

ARDX Fundamentals

ARDX Revenue

Revenue (TTM)

124.5M

Rev. Growth (Yr)

-22.22%

Rev. Growth (Qtr)

-39.06%

ARDX Earnings

Earnings (TTM)

-66.1M

Earnings Growth (Yr)

-369.3%

Earnings Growth (Qtr)

-534.48%

Breaking Down ARDX Revenue

Last 7 days

-7.8%

Last 30 days

-16.2%

Last 90 days

-18.3%

Trailing 12 Months

34.4%

How does ARDX drawdown profile look like?

ARDX Financial Health

Current Ratio

4.88

ARDX Investor Care

Shares Dilution (1Y)

12.68%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	63.1M	82.9M	134.3M	124.5M
2022	4.0M	5.2M	9.0M	52.2M
2021	12.9M	12.4M	10.9M	10.1M
2020	6.6M	8.3M	8.0M	7.6M
2019	0	0	3.3M	5.5M
2018	44.3M	44.4M	44.5M	2.6M
2017	0	0	0	60.1M
2015	29.0M	38.0M	30.4M	24.0M
2014	30.9M	32.8M	33.8M	31.6M
2013	11.3M	17.2M	23.0M	28.9M
2012	0	0	0	5.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ardelyx Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	raab michael	sold	-52,923	7.0565	-7,500	president & ceo
Apr 01, 2024	raab michael	sold	-11,096	7.31	-1,518	president & ceo
Mar 25, 2024	kelliher mike	acquired	-	-	160,000	see remarks
Mar 20, 2024	grammer elizabeth a	sold	-664,978	7.7323	-86,000	see remarks
Mar 15, 2024	blanks robert	gifted	-	-	-1,000	see remarks
Feb 26, 2024	rosenbaum david p.	sold	-47,683	9.2	-5,183	chief development officer
Feb 20, 2024	grammer elizabeth a	sold	-38,763	8.7463	-4,432	see remarks
Feb 20, 2024	felsch robert ora	sold	-20,571	8.7463	-2,352	see remarks
Feb 20, 2024	williams laura a	sold	-42,008	8.7463	-4,803	chief medical officer
Feb 20, 2024	blanks robert	sold	-43,880	8.7463	-5,017	see remarks

Which funds bought or sold ARDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	37.16	1,219,760	3,203,440	0.17%
Apr 16, 2024	WEBSTER BANK, N. A.	new	-	3,650	3,650	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	new	-	144,160	144,160	-%
Apr 15, 2024	FIRST CITIZENS BANK & TRUST CO	unchanged	-	55,000	365,000	0.01%
Apr 12, 2024	Ausdal Financial Partners, Inc.	new	-	111,055	111,055	0.01%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	sold off	-100	-12,400	-	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	NBC SECURITIES, INC.	unchanged	-	-	1,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	9.78	-431	4,833	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-28,560	-	-%

Are Funds Buying or Selling ARDX?

Are funds buying ARDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARDX

No. of Funds

ARDX Alerts

1 major insider sales recently.

Unveiling Ardelyx Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	janus henderson group plc	10.6%	24,658,820	SC 13G/A
Feb 13, 2024	vanguard group inc	5.61%	13,026,046	SC 13G
Jan 31, 2024	millennium management llc	0.0%	6,286	SC 13G/A
Jan 30, 2024	state street corp	7.37%	17,102,598	SC 13G/A
Jan 26, 2024	blackrock inc.	7.2%	16,776,055	SC 13G
Jul 10, 2023	state street corp	10.46%	22,437,564	SC 13G
Feb 14, 2023	deep track capital, lp	0%	0	SC 13G/A
Feb 07, 2023	millennium management llc	5.1%	10,162,045	SC 13G
Jan 27, 2023	millennium management llc	5.4%	10,634,329	SC 13G/A
Jan 10, 2023	janus henderson group plc	10.5%	19,774,333	SC 13G

Recent SEC filings of Ardelyx Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 27, 2024	3	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 20, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	8-K	Current Report

Peers (Alternatives to Ardelyx Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Ardelyx Inc News

Latest updates

Ardelyx Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4	2018Q3	2018Q2
Revenue	-39.1%	34,363,000	56,391,000	22,333,000	11,369,000	44,178,000	4,986,000	2,526,000	468,000	1,029,000	1,173,000	1,313,000	6,582,000	1,809,000	2,713,000	1,836,000	1,213,000	2,250,000	3,013,000	85,000	172,000	30,000
Cost Of Revenue	-	-	-	-	1,537,000	3,162,000	732,000	138,000	85,000	-	-	-	1,000,000	4,000	-	141,000	-	-	600,000	-	2,000	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,250,000	2,413,000	85,000	170,000	30,000
Costs and Expenses	36.8%	56,503,500	41,301,000	35,468,000	37,433,000	28,830,500	26,134,000	28,603,000	28,275,000	35,302,000	43,409,000	46,145,000	38,587,000	29,452,000	19,874,000	26,043,000	22,982,000	21,098,000	25,102,000	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22,982,000	21,098,000	24,502,000	27,461,000	23,902,000	22,184,000
S&GA Expenses	46.2%	47,748,000	32,664,000	27,186,000	26,803,000	19,731,000	18,667,000	18,862,000	19,339,000	15,334,000	19,714,000	20,124,000	17,131,000	11,343,000	7,634,000	7,038,000	7,138,000	6,857,000	6,922,000	5,425,000	5,961,000	6,138,000
R&D Expenses	10.3%	9,524,000	8,637,000	8,282,000	9,093,000	9,142,000	7,467,000	9,741,000	8,851,000	20,968,000	23,695,000	26,021,000	20,456,000	18,105,000	12,240,000	18,864,000	15,844,000	14,241,000	17,580,000	22,036,000	17,941,000	16,046,000
EBITDA Margin	-203.1%	-0.48	-0.16	-0.62	-0.98	-1.20	-12.12	-24.70	-36.68	-14.94	-13.10	-9.51	-7.56	-	-	-	-	-	-	-	-	-
Interest Expenses	57.2%	1,740,000	1,107,000	1,075,000	1,028,000	991,000	886,000	777,000	746,000	984,000	1,216,000	1,202,000	1,100,000	1,314,000	1,202,000	1,226,000	1,357,000	1,398,000	1,443,000	-	1,404,000	692,000
Income Taxes	66.5%	333,000	200,000	-	14,000	-	-	6,000	2,000	-	1,000	2,000	1,000	2,000	-	-	-	-	301,000	-2,000	-	2,000
Earnings Before Taxes	-516.9%	-28,469,000	6,829,000	-17,121,000	-26,759,000	10,695,000	-22,893,000	-26,932,000	-28,069,000	-36,234,000	-43,586,000	-45,187,000	-33,154,000	-28,874,000	-18,108,000	-24,956,000	-22,373,000	-19,790,000	-23,238,000	-27,864,000	-24,126,000	-22,289,000
EBT Margin	-168.2%	-0.53	-0.20	-0.68	-1.04	-1.29	-12.67	-25.95	-38.43	-15.66	-13.86	-10.09	-8.12	-	-	-	-	-	-	-	-	-
Net Income	-534.5%	-28,802,000	6,629,000	-17,121,000	-26,773,000	10,695,000	-22,893,000	-26,938,000	-28,071,000	-36,234,000	-43,587,000	-45,189,000	-33,155,000	-28,876,000	-18,108,000	-24,956,000	-22,373,000	-19,790,000	-23,539,000	-27,862,000	-24,126,000	-22,291,000
Net Income Margin	-168.3%	-0.53	-0.20	-0.68	-1.05	-1.29	-12.67	-25.95	-38.43	-15.66	-13.86	-10.09	-8.12	-	-	-	-	-	-	-	-	-
Free Cashflow	59.6%	-8,761,000	-21,661,000	-14,830,000	-44,809,000	14,229,000	-25,427,000	-31,281,000	-27,620,000	-39,374,000	-35,034,000	-35,015,000	-44,995,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.8%	298	289	211	217	190	145	132	129	150	171	205	210	202	199	217	235	260	119	138	166	183
Current Assets	2.0%	246	241	162	167	154	120	114	114	134	153	186	205	195	194	212	229	252	111	127	154	176
Cash Equivalents	-36.4%	21.00	34.00	30.00	92.00	96.00	62.00	53.00	47.00	72.00	75.00	87.00	84.00	91.00	91.00	100	106	181	93.00	90.00	92.00	79.00
Inventory	-	-	-	-	-	-	-	5.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-9.6%	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	5.00	6.00
Liabilities	33.1%	131	98.00	88.00	92.00	92.00	78.00	79.00	65.00	67.00	89.00	87.00	79.00	75.00	67.00	71.00	68.00	73.00	70.00	69.00	74.00	68.00
Current Liabilities	15.8%	50.00	44.00	62.00	63.00	66.00	52.00	49.00	48.00	53.00	69.00	58.00	42.00	28.00	17.00	34.00	23.00	22.00	18.00	16.00	21.00	18.00
LT Debt, Current	-	-	-	-	-	-	27.00	26.00	26.00	32.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-12.7%	167	191	123	125	98.00	67.00	53.00	64.00	83.00	81.00	118	131	126	131	146	168	187	49.00	69.00	92.00	116
Retained Earnings	-3.5%	-846	-817	-824	-806	-780	-790	-767	-741	-712	-676	-633	-587	-554	-525	-507	-482	-460	-440	-417	-391	-365
Additional Paid-In Capital	0.4%	1,013	1,009	947	932	879	858	821	805	796	758	751	719	681	657	654	651	647	490	486	483	481
Shares Outstanding	0.1%	232	232	218	214	199	147	146	131	104	100	100	97.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	725	-	-	-	89.00	-	-	-	769	-	-	-	612	-	-	-	126	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	59.4%	-8,718	-21,467	-14,737	-44,795	14,284	-25,427	-31,281	-27,620	-39,469	-34,589	-34,276	-44,217	-17,590	-19,877	-19,022	-24,946	-11,137	-20,614	-27,820	-16,913	-18,436
Share Based Compensation	12.6%	3,930	3,489	3,199	2,912	1,926	1,848	3,254	3,722	3,471	2,262	3,219	3,087	2,434	2,527	2,674	2,948	2,212	3,879	1,923	1,922	2,250
Cashflow From Investing	9.6%	-29,567	-32,697	-59,207	-9,777	1,441	-832	15,474	2,332	22,096	18,133	8,234	2,485	-3,570	9,594	13,417	-50,883	-55,461	23,448	25,405	29,981	22,190
Cashflow From Financing	-55.1%	25,988	57,873	11,515	50,919	18,787	34,479	22,138	-63.00	14,513	4,999	28,717	34,770	21,183	798	204	591	155,058	213	5.00	200	-1.00

ARDX Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 124,456	$ 52,158	$ 10,097
Cost of goods sold:
Total cost of goods sold	17,795	4,117	1,000
Operating expenses:
Research and development	35,536	35,201	91,140
Selling, general and administrative	134,401	76,599	72,303
Total operating expenses	169,937	111,800	163,443
Loss from operations	(63,276)	(63,759)	(154,346)
Interest expense	(4,950)	(3,400)	(4,502)
Non-cash interest expense related to the sale of future royalties	(3,924)	(1,673)	0
Other income, net	6,630	1,633	687
Loss before provision for income taxes	(65,520)	(67,199)	(158,161)
Provision for income taxes	547	8	4
Net loss	$ (66,067)	$ (67,207)	$ (158,165)
Net loss per share of common stock - basic (in dollars per share)	$ (0.30)	$ (0.42)	$ (1.52)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.30)	$ (0.42)	$ (1.52)
Shares used in computing net loss per share - basic (in shares)	219,331,253	158,690,083	104,205,645
Shares used in computing net loss per share - diluted (in shares)	219,331,253	158,690,083	104,205,645
Comprehensive loss:
Net loss	$ (66,067)	$ (67,207)	$ (158,165)
Unrealized gains (losses) on available-for-sale securities	278	(48)	(2)
Comprehensive loss	(65,789)	(67,255)	(158,167)
Product sales, net
Revenues:
Total revenues	82,526	15,600	0
Cost of goods sold:
Total cost of goods sold	2,323	566	0
Licensing revenue
Revenues:
Total revenues	35,809	35,031	5,013
Product supply revenue
Revenues:
Total revenues	6,121	1,527	907
Collaborative development revenue
Revenues:
Total revenues	0	0	4,177
Other cost of revenue
Cost of goods sold:
Total cost of goods sold	$ 15,472	$ 3,551	$ 1,000

ARDX Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 21,470,000	$ 96,140,000
Short-term investments	162,829,000	27,769,000
Accounts receivable	22,031,000	7,733,000
Inventory	12,448,000	3,282,000
Prepaid commercial manufacturing	18,925,000	13,567,000
Prepaid expenses and other current assets	8,408,000	5,112,000
Total current assets	246,111,000	153,603,000
Property and equipment, net	1,009,000	1,223,000
Inventory, non-current	37,039,000	25,064,000
Prepaid commercial manufacturing, non-current	4,235,000	0
Right-of-use assets	5,589,000	9,295,000
Other assets	3,596,000	881,000
Total assets	297,579,000	190,066,000
Current liabilities:
Accounts payable	11,138,000	10,859,000
Accrued compensation and benefits	12,597,000	7,548,000
Current portion of operating lease liability	4,435,000	3,894,000
Current portion of long-term debt	0	26,711,000
Deferred revenue	7,182,000	4,211,000
Accrued expenses and other current liabilities	15,041,000	12,380,000
Total current liabilities	50,393,000	65,603,000
Operating lease liability, net of current portion	1,725,000	5,855,000
Long-term debt, net of current portion	49,822,000	0
Deferred revenue, non-current	8,644,000	9,025,000
Deferred royalty obligation related to the sale of future royalties	20,179,000	11,254,000
Total liabilities	130,763,000	91,737,000
Commitments and contingencies (Note 20)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 and 300,000,000 shares authorized; 232,453,190 and 198,575,016 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.	23,000	20,000
Additional paid-in capital	1,012,773,000	878,500,000
Accumulated deficit	(846,204,000)	(780,137,000)
Accumulated other comprehensive income (loss)	224,000	(54,000)
Total stockholders’ equity	166,816,000	98,329,000
Total liabilities and stockholders’ equity	$ 297,579,000	$ 190,066,000

About Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Michael G. Raab
WEBSITE	ardelyx.com
INDUSTRY	Biotechnology
EMPLOYEES	133

Ardelyx Inc Frequently Asked Questions

What is the ticker symbol for Ardelyx Inc? What does ARDX stand for in stocks?

ARDX is the stock ticker symbol of Ardelyx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ardelyx Inc (ARDX)?

As of Wed Apr 17 2024, market cap of Ardelyx Inc is 1.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARDX stock?

You can check ARDX's fair value in chart for subscribers.

What is the fair value of ARDX stock?

You can check ARDX's fair value in chart for subscribers. The fair value of Ardelyx Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ardelyx Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ardelyx Inc a good stock to buy?

The fair value guage provides a quick view whether ARDX is over valued or under valued. Whether Ardelyx Inc is cheap or expensive depends on the assumptions which impact Ardelyx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARDX.

What is Ardelyx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, ARDX's PE ratio (Price to Earnings) is -23.07 and Price to Sales (PS) ratio is 12.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDX PE ratio will change depending on the future growth rate expectations of investors.